Abbvie Helps Ablynx 'Grow Up' With $840M Collaboration

Moran, Nuala
September 2013
BioWorld International;9/25/2013, Vol. 18 Issue 39, p1
The article reports on a licensing agreement signed between pharmaceutical companies Ablynx NV and Abbvie Inc. in 2013. The 840-million-dollar agreement focuses on developing Ablynx's ALX-0061 nanobody targeting the cytokine interleukin-6 receptor (IL-6R) for the treatment of rheumatoid arthritis and systemic lupus erythematosus. Chief executive officer (CEO) Ed Moses stated that Abbvie is the ideal pharmaceutical partner for his company because of its significant experience in rheumatology.


Related Articles

  • Abbvie Helps Ablynx 'Grow Up' with $840M. Moran, Nuala // BioWorld Today;9/24/2013, Vol. 24 Issue 183, p1 

    The article reports that biopharmaceutical firm Ablynx NV has signed a licensing agreement with drug company Abbvie Inc. for Ablynx's ALX-0061 nanobody that is aimed at the cytokine interleukin-6 receptor (IL-6R), for the treatment of rheumatoid arthritis and systemic lupus erythematosus. Under...

  • Galapogos, AbbVie In CF Alliance.  // Contract Pharma;Oct2013, Vol. 15 Issue 8, p130 

    The article information on various reports related to business alliances and partnerships of several pharmaceutical companies. The AbbVie and Galapagos NV, had move into global alliance intended to develop and commercializs therapies for cystic fibrosis (CF). The expansion of partnership between...

  • Phase II Clinical Trials Update: February 2013.  // BioWorld Insight;3/11/2013, Vol. 21 Issue 11, p10 

    A table is presented which lists the February 2013 update for the Phase II clinical trials which include ALX-0061 from Ablynx NV, ABT-199 from AbbVie Inc., and StemEx from Gamida Cell Ltd.

  • 'Good Week' for Ablynx Continues: Discovery Deal with Merck Serono. Moran, Nuala // BioWorld Today;9/27/2013, Vol. 24 Issue 186, p1 

    The article reports on a collaborative discovery deal secured by biopharmaceutical firm Ablynx NV from pharmaceutical company Merck Serono, wherein a discovery unit will be set up at Ablynx. Aside from the creation of the discovery unit, Merck Serono will also finance the research for four years...

  • Ablynx, Merck Ink Neuroscience Nanobody Deal for up to $590M. Moran, Nuala // BioWorld Today;10/3/2012, Vol. 23 Issue 192, p1 

    The article reports on the neuroscience deal signed by Ablynx Inc. with Merck & Co. Inc. The deal is valued at 456.5 million euros or 589.5 million U.S. dollars. Ablynx is expected to receive an up front fee of 6.5 million euros, as well as two million euros in research fee as part of the...

  • Small nanobody drugs win big backing from pharma. Williams, Sarah CP // Nature Medicine;Nov2013, Vol. 19 Issue 11, p1355 

    The article offers information related to an agreement of worth 840 million U.S. dollars between the Belgian pharmaceutical firm Ablynx NV and Illinois-based pharmaceutical company AbbVie Inc. for co-development of one of Ablynx's so-called nanobodies, ALX-0061 for the treatment of rheumatoid...

  • The Puzzle Master. Donahue, Marylyn // Pharmaceutical Executive;Jul2015, Vol. 35 Issue 7, p27 

    The article offers the author's insights on associate director of marketing Gaby Mishev at Genentech Inc., a biotechnology company. Topics discussed include Mishev started in the pharmaceutical industry as an analyst at pharmaceutical company Roche in 2006, Genentech's culture, and her...

  • Financings Roundup.  // BioWorld Today;3/ 4/2013, Vol. 24 Issue 41, p2 

    The article offers world news briefs related corporate finance which include the redemption of 500 million dollars by Teva Pharmaceuticals Industries Ltd., the funds worth 31.5 euros raised by Ablynx NV through a private placement of new shares and the plan of EntreMed Inc. to purchase 10.7...

  • Ablynx, Eddingpharm Ink Chinese Pact On RANKL Inhibitor.  // BioWorld Today;10/21/2013, Vol. 24 Issue 202, p1 

    The article reports that Ablynx NV has entered a regional agreement with Chinese specialty pharmaceutical firm Eddingpharm Company Limited for the development and commercialization of its anti-RANKL nanobody ALX-O141. According to the author, the deal has a potential upside into a program that...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics